Gyre Therapeutics, Inc. (NASDAQ:GYRE) Receives Average Recommendation of “Hold” from Brokerages

Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) have earned a consensus rating of “Hold” from the five brokerages that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have given a buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $17.00.

A number of brokerages have recently weighed in on GYRE. Jefferies Financial Group initiated coverage on Gyre Therapeutics in a research report on Friday, October 10th. They set a “buy” rating and a $16.00 price target on the stock. Zacks Research upgraded Gyre Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Friday, November 14th. Wall Street Zen raised Gyre Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, November 15th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Gyre Therapeutics in a report on Thursday, January 22nd.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Bank of America Corp DE increased its stake in shares of Gyre Therapeutics by 28.8% in the second quarter. Bank of America Corp DE now owns 6,277 shares of the company’s stock valued at $46,000 after purchasing an additional 1,402 shares during the period. Alliancebernstein L.P. grew its holdings in Gyre Therapeutics by 9.5% in the 3rd quarter. Alliancebernstein L.P. now owns 21,830 shares of the company’s stock worth $163,000 after buying an additional 1,900 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in Gyre Therapeutics by 84.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 6,461 shares of the company’s stock worth $47,000 after buying an additional 2,961 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Gyre Therapeutics by 77.8% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,413 shares of the company’s stock valued at $54,000 after acquiring an additional 3,244 shares during the period. Finally, State of Alaska Department of Revenue bought a new stake in Gyre Therapeutics during the 3rd quarter valued at $38,000. 23.99% of the stock is owned by institutional investors and hedge funds.

Gyre Therapeutics Stock Down 0.7%

GYRE opened at $8.03 on Thursday. The company’s 50-day moving average price is $7.62 and its 200 day moving average price is $7.65. Gyre Therapeutics has a fifty-two week low of $6.11 and a fifty-two week high of $13.75. The firm has a market cap of $773.53 million, a price-to-earnings ratio of 267.76 and a beta of 1.99.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.